MONTREAL--(BUSINESS WIRE)--Angiochem, Inc., a clinical stage biotechnology company, announced today that preclinical and clinical data demonstrating the broad applicability of its Engineered Peptide Compounds (EPiC) technology to physiologically cross the blood brain barrier (BBB), were presented in a panel at the 6th Annual Peptide Therapeutics Foundation Symposium, October 21, 2011, at the Salk Institute in La Jolla, CA. These data demonstrated that by targeting the lipoprotein receptor-related protein (LRP-1), which is highly expressed on the surface of the BBB, Angiochem’s proprietary EPiC technology enables the creation of breakthrough drugs that physiologically crosses the BBB for the treatment of brain and brain-related diseases such as cancer, pain, diabetes/obesity and Parkinson’s disease. Importantly, this data demonstrated that the EPiC technology is broadly applicable to small molecules, peptides, proteins and biologics.
“By utilizing our proprietary EPiC technology, Angiochem has identified sequences of amino acids that bind to LRP-1, one of the most expressed receptors on the surface of the BBB, to create new chemical entities that cross the BBB physiologically and act directly in the brain to treat brain diseases,” said Jean-Paul Castaigne, MD, President and CEO of Angiochem. “This approach has been validated in humans in two trials with over 119 patients and in several preclinical models ranging from cancer to pain, obesity and even CNS diseases such as Parkinson’s.”
Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough drugs that are leveraging the LRP-1 mediated pathway to cross the blood-brain barrier (BBB) to treat brain diseases. These new Engineered Peptide Compounds (EPiC) have the potential to address significant medical needs, many of which cannot be effectively addressed due to the fundamental physiological challenge the blood-brain barrier presents for therapeutic intervention. Angiochem is developing a deep and broad product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including brain cancer, neurodegenerative and metabolic diseases, pain, and many others. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the company, please visit http://www.angiochem.com.